ArticleRMD open2023
Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis.
Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 65 citations in OpenAlex.
- Constrictive Pericarditis and Bilateral Pleural Effusions Unmasked in an HLA-B27 Positive Patient.JACC. Case reports · 2026Article
- A Comprehensive HLA-DR4 MHC Class II Tetramer Platform for the Detection and Functional Validation of Post-Translational Modification Neoantigens.International journal of molecular sciences · 2026Article
- Article
- The 60Rheumatology and immunology research · 2026Article
- Recent updates in human leukocyte antigen B27-associated uveitis.Indian journal of ophthalmology · 2026Review
- Personalized Medicine, Storied Past, Contentious Present, Promising Future.Journal of personalized medicine · 2026Article
- Increased blood levels of neutrophil- and platelet-derived markers in patients with radiographic axial spondyloarthritis: a pilot study.Rheumatology international · 2026Article
- Therapeutic Insights and Immune Pathway Connections Revealed by Core Symptom Gene Network Analysis in Ankylosing Spondylitis.Current issues in molecular biology · 2026Article
- Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.Rheumatology and therapy · 2026Article
- Circulating angiogenic T cells as potential immune-vascular biomarkers associated with disease activity in axial spondyloarthritis.Frontiers in immunology · 2026Article
- Nanozymes in Therapeutic Prospects and Challenges for Autoimmune Diseases.International journal of nanomedicine · 2026Review
- Genomic information contributing to the understanding of rheumatic diseases.EULAR rheumatology open · 2025Article
- What can Animal Models tell us About T Cells in Spondyloarthritis Pathogenesis?Current rheumatology reports · 2025Review
- The Role of Diet in Modulating Inflammation and Oxidative Stress in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.Nutrients · 2025Review
- The rapid detection of human HLA-B*27 gene based on BASIC isothermal detection.Scientific reports · 2025Article
- Proteomic Profiling of Inflammatory Protein Dysregulation in HLA-B27-Positive Ankylosing Spondylitis: Molecular Signatures and Potential Biomarkers.Biomolecules · 2025Article
- Distribution of human leukocyte antigen B27 (HLA-B27) in Slovak patients.Journal of applied biomedicine · 2025Article
- Fast, Present and Future of the Concept of Spondyloarthritis.Current rheumatology reports · 2025Review
- Emerging biochemical, microbial and immunological evidence in the search for why HLA-BCell chemical biology · 2025Review
- Relationships between emotional state, sleep disturbance and health-related quality of life in patients with axial spondyloarthritis.Clinical rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human lymphocyte antigen B27 (HLA B27) is a member of the HLA class I family of genes in the major histocompatibility complex whose name goes back to its discovery in studies of transplanted tissue compatibility. Its prevalence in the mid-European population is about 8%. The association of HLA B27 alleles with ankylosing spondylitis (AS), a highly heritable disease, which is part of the spectrum of axial spondyloarthritis (axSpA), was discovered 50 years ago. HLA B27 explains less than 30% of the total genetic load. About 60%-90% of axSpA patients worldwide carry HLA B27. The prevalence of the disease is linked to the frequency of HLA B27 in the population which implies that there are relevant differences. Among the roughly 200 subtypes known there are two which are not disease associated. The function of HLA class I molecules is to present peptides to the immune system to defend the organism against microbes targeted by CD8+T cells. This is much supported by the role of the endoplasmic reticulum aminopeptidase 1 (ERAP 1) in AS, an enzyme that is responsible for the intracellular trimming of peptides, since polymorphisms of this gene are only associated with HLA-B27+ disease. The arthritogenic peptide hypothesis trying to explain the pathogenesis of AS is based on that very immune function assuming that also self peptides can be presented. HLA-B27 also plays an important role in classification, diagnosis and severitiy of axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.